We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Tissue Implant as Alternative to Gene Therapy

By Biotechdaily staff writers
Posted on 15 Jul 2002
Using a patient's own tissue as the site of production and delivery of precise amounts of protein is a new alternative to gene therapy and other protein injections. More...


A tiny strip of skin is taken from the patient and then genetically engineered in vitro by the introduction of specific genes via viral vectors. The small bit of tissue is transformed into a "factory”, called Biopump, which will produce a therapeutic protein for the treatment of diseases such as anemia, muscle wasting, hepatitis and other disorders. After being implanted under the skin, this modified tissue begins to deliver a measured supply of protein. Protein production can last for many months, and the therapy can be safely and immediately stopped by simply removing the implant.

"Biopump is intended as an alternative to intravenous protein injections, gene therapy and slow-release protein technologies,” said Dr. Andrew Pearlman, CEO of Medgenics, the developer of Biopump. "Injections are an inefficient way to deliver therapeutic proteins because there is an initial spike in the concentration of the proteins created at the time of intravenous injection, which can result in toxic side effects. Conversely, there is a rapid decline in protein concentration to levels that are suboptimal in therapeutic terms, and the patient must wait until the next injection until the level of therapeutic protein can be restored.”

The shape of the tissue strip is critical to the BioPump method. It has been selected to allow the tissue to live outside of the body for up to several months while it is being altered genetically. It is substantial enough to comprise a viable tissue but sufficiently thin so that all cells are close enough to the support medium to receive nutrients through diffusion. Only minimal medium is needed and there is no use of animal by-products or serum.

"This is a critical advantage over gene therapy, which is an attempt to produce a drug inside the body by injecting a virus with a desired gene that will initiate the production of a certain protein by body cells. However, it cannot be known how much protein will be produced by protein therapy or from which cells, and there is no practical way to halt gene therapy if needed,” explained Dr. Pearlman. "If you want our treatment to stop, you simply pull it out,” said Dr. Pearlman.




Related Links:
Medigenics

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.